<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693056</url>
  </required_header>
  <id_info>
    <org_study_id>RX-10100-P2A-001</org_study_id>
    <nct_id>NCT00693056</nct_id>
  </id_info>
  <brief_title>Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)</brief_title>
  <official_title>A Double-Blinded, Randomized, Placebo-Controlled, Dose-Exploring Study of RX-10100 for Eight Weeks of On-Demand Administration in Subjects With Erectile Dysfunction (ED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rexahn Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rexahn Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this Phase IIa trial is to determine the effective doses and
      treatment period for an upcoming RX-10100 Phase IIb trial in subjects with erectile
      dysfunction (ED). The secondary objectives of this trial are to evaluate the safety and the
      quality of life in subjects with ED receiving RX-10100 treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scores on IIEF-EF Questionnaires and on SEP Questions II and III</measure>
    <time_frame>Weeks 4 and 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores on other domains of IIEF, other questions on Subject Diaries, RigiScan measurement, and ED-QoL questionnaires</measure>
    <time_frame>Weeks 4 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Erectile Dysfunction (ED)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (w/o API)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10100 5mg</intervention_name>
    <description>5 mg/dose of RX-10100</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zoraxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10100 10mg</intervention_name>
    <description>10 mg/dose of RX-10100</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Zoraxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-10100 15mg</intervention_name>
    <description>15 mg/dose of RX-10100</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Zoraxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have had ED for at least six months

          -  Stable, heterosexual relationship for at least 3 months

          -  Make at least one attempt of sexual intercourse per week during the untreated, 2-week
             screening period

          -  At least 50% of attempts of sexual intercourse during the untreated baseline period
             must be unsuccessful

          -  'Moderate' or 'mild to moderate' ED, defined as an IIEF-EF domain score between 11 and
             21 measured

        Exclusion Criteria:

          -  Following previous or current medical conditions

               -  Any unstable medical, psychiatric, or substance abuse disorder

               -  Penile anatomical abnormalities

               -  Primary hypoactive sexual desire

               -  Spinal cord injury

               -  Hypogonadism

               -  Surgical prostatectomy

               -  Stable or unstable angina pectoris

               -  Myocardial infarction, stroke, or life-threatening arrhythmia

               -  Uncontrolled atrial fibrillation/flutter at screening

               -  Severe chronic or acute liver disease

               -  Moderate or severe hepatic impairment

               -  Clinically significant chronic hematological disease

               -  Bleeding disorder

               -  Significant active peptic ulcer disease

               -  Resting hypotension or hypertension

               -  Malignancy (cancers)

               -  NYHA Class II to IV heart failures

               -  Positive test for Hepatitis B surface antigen (HBsAg) or Hepatitis C

               -  Symptomatic postural hypotension

          -  Following concomitant medication

               -  Androgens or estrogens

               -  Anti-androgens

               -  Potent inhibitors of cytochrome P450 3A4

               -  Any other investigational drug within 30 days before Visit 1

               -  Any treatment for ED within 7 days before Visit 1 or during the study

               -  Antibiotics in the penicillin class

          -  Following abnormal laboratory values

               -  Serum total testosterone level (at least 25% lower)

               -  Serum creatinine (&gt; 3.0 mg/dl)

               -  Elevation of AST and/or ALT (&gt; 3 times the upper limit of normal)

               -  Diabetic subjects with an HbAlc (&gt; 6.5%)

          -  Subjects with known hypersensitivity to amoxicillin

          -  Subjects with a history of unresponsiveness to any PDE5 Inhibitor treatment or a
             history of significant side effects leading to its treatment discontinuation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyungjoo Hugh Lee, MS</last_name>
    <role>Study Director</role>
    <affiliation>Rexahn Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <zip>20770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westampton</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>May 4, 2009</last_update_submitted>
  <last_update_submitted_qc>May 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hyungjoo Lee / Associate Director, Product Development Management</name_title>
    <organization>Rexahn Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Erectile Dysfunctions</keyword>
  <keyword>ED</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

